| Literature DB >> 24369067 |
Ellen M Unterwald, Michelle E Page, Timothy B Brown, Jonathan S Miller, Marta Ruiz, Karen A Pescatore, Baoji Xu, Louis French Reichardt, Joel Beverley, Bin Tang, Heinz Steiner, Elizabeth A Thomas, Michelle E Ehrlich1.
Abstract
BACKGROUND: The high affinity tyrosine kinase receptor, TrkB, is the primary receptor for brain derived neurotrophic factor (BDNF) and plays an important role in development, maintenance and plasticity of the striatal output medium size spiny neuron. The striatal BDNF/TrkB system is thereby implicated in many physiologic and pathophysiologic processes, the latter including mood disorders, addiction, and Huntington's disease. We crossed a mouse harboring a transgene directing cre-recombinase expression primarily to postnatal, dorsal striatal medium spiny neurons, to a mouse containing a floxed TrkB allele (fB) mouse designed for deletion of TrkB to determine its role in the adult striatum.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24369067 PMCID: PMC3880973 DOI: 10.1186/1750-1326-8-47
Source DB: PubMed Journal: Mol Neurodegener ISSN: 1750-1326 Impact factor: 14.195
Figure 1Baseline striatal TrkB level and locomotor activity in D9ΔTrkB mice. (a) Baseline levels of striatal TrkB.FL and TrkB.T1 are equal in fB/fB male and female mice. Densitometric values were normalized to actin. Blot is representative of N = 6, p > 0.05 (t-test). (b) Relative to fB/fB, D9ΔTrkB male and female mice demonstrate approximately a 50% decrease in striatal TrkB.FL (N = 3–4,*** P < 0.005, t-test). There is a trend towards a small decrease in TrkB.T1 (N = 3, P = 0.06, t-test). Densitometric values were normalized to actin, and fB/fB levels were arbitrarily set to equal 1. (c) Down-regulation of striatal MSN TrkB.FL does not alter baseline total activity, but there is a genotype-independent increase in activity in female mice relative to males (N = 8-12/group, ** P < 0.01 two-way ANOVA for sex factor).
Figure 2D9ΔTrkB male and female mice display genotype- and sex-dependent differences in depression- and anxiety-like behaviors and in cocaine place preference. (a) In the forced swim test, male D9ΔTrkB mice had lower immobility scores versus male fB/fB, but there was no difference for females (*P < 0.05 fB/fB vs D9ΔTrkB males, N = 10-18/group). (b) In the elevated plus maze, male D9ΔTrkB spent a greater amount of time in the open arms versus male fB/fB, but there was no difference for females (*P < 0.05 fB/fB vs D9ΔTrkB males, N = 8-10/group). (c) Cocaine produced a larger place preference in D9ΔTrkB females versus fB/fB females (*P < 0.05, N = 7/group). Males showed a place preference for cocaine that was genotype-independent. fB/fB males showed a significantly greater place preference than fB/fB females (#P < 0.05, N = 7-8/group). (d) Acute cocaine, 20 mg/kg, increased activity in females of both genotypes (*p < 0.05, ***P < 0.001 saline versus cocaine, N = 5-6/group). Cocaine produced greater hyperactivity in female D9ΔTrkB mice versus fB/fB (### P < 0.001, N = 5-6/group). (e) Female mice were injected with saline or cocaine, 20 mg/kg, for 5 days. After a 6-day drug-free period, a cocaine challenge injection, 15 mg/kg, produced greater hyperactivity in D9ΔTrkB mice pretreated with cocaine versus fB/fB controls pretreated with cocaine (###P < 0.001, N = 5-6/group) In addition, D9ΔTrkB mice pretreated with cocaine showed greater hyperactivity in response to the cocaine challenge than did D9ΔTrkB mice pretreated with saline (**P < 0.01, N = 5–6), demonstrating that locomotor sensitization was greater in the D9ΔTrkB female mice.
Summary of gene expression changes as determined by hybridization (percent change in D9ΔTrkB relative to fB/fB)
| (−) 51%, P < 0.01 | (−) 40%, P < 0.05 | |
| (−) 38%, P < 0.001 | (−) 18%, P < 0.05 | |
| (−) 15%, P < 0.01 | No change | |
| (−) 20%, P < 0.05 | No change | |
| (+) 30%,P < 0.05 | No change |
Figure 3Down-regulation of striatal MSN TrkB leads to specific alterations in expression of MSN-enriched transcripts in male mice. (a) Diagram of dorsal striatal regions (middle level, 4.2 mm rostral to the interaural line) used for quantitation of results of in situ hybridization of Ntrk2, Penk, Tacr1, Ppp1r1b and Pdyn mRNAs. S = striatum, m = medial, c = central, l = lateral, v = ventral. (b) Densitometry of representative autoradiograms of Penk mRNA in situ hybridization on mid-level striatal sections shows a 40% reduction in preproenkephalin mRNA level (N = 3 fB/fB, N = 4 D9ΔTrkB, P < 0.01, t-test). (c) RT-qPCR was performed on samples derived from the dorsal striatum of male mice (N = 4/genotype), confirming a significant decrease in Ntrk2 and Penk mRNAs in D9ΔTrkB mice versus fB/fB mice (*P < 0.01, t-test) and demonstrating greater than 50% decrease in Calb1 mRNA (*P < 0.01, t-test).
Figure 4Microarray analysis of dorsal striatal samples from female D9ΔTrkB mice reveals widespread alterations in gene expression (see Table 2). (a) RT-qPCR assay of Ryr1, Slit2, Egr1, Ntrk3, Vgf, Per2, and Lynx2 mRNAs validated the results of the microarray analysis, whereas assay of Adra2 mRNA did not show a difference between genotypes (N = 4/genotype; * P < 0.05,**P < 0.01,***P < 0.001). (b) RT-qPCR assay of Ryr1, Per2, Ptpn5 and Vgf mRNAs in striatal samples from male mice (N = 4/genotype) showed reductions in transcripts similar to those observed in samples from females (**P < 0.01,***P < 0.001). (c) Venn diagram illustrating that of the top 325 genes with mRNA levels altered at the P < 0.005 level in D9ΔTrkB mice, only 144 were altered in BDNF-null mice (from [18]) at the least stringent level of significance, P < 0.05.
Top canonical pathways associated with TrkB deletion in mouse striatal MSNs
| Thrombin signaling | 2.69E + 00 | 5.34E-02 | ARHGEF10, MPRIP, GATA1, RHOT2, ADCY1, GNB5, CAMK1G, HRAS, PRKCH, GNG7, PRKCB |
| Protein kinase A signaling | 2.63E + 00 | 4.28E-02 | SHH, PTPN7, PTPRE, SMAD3, DUSP6, GNB5, PTPN5, TCF7, GNG7, PTEN, ADD3, ADCY1, SMAD4, RYR1, PRKCH, CDC16, PRKCB |
| Galpha(i) signaling | 2.44E + 00 | 6.06E-02 | GRM8, NPY1R, ADCY1, GNB5, HRAS, ADRA2C, STAT3, GNG7 |
| Prolactin signaling | 2.39E + 00 | 7.50E-02 | HRAS, PRKCH, STAT3, SOCS5, TCF7, PRKCB |
| CXCR4 signaling | 2.36E + 00 | 5.36E-02 | EGR1, RHOT2, ADCY1, GNB5, HRAS, PRKCH, ELMO1, GNG7, PRKCB |
| Glutamate receptor signaling | 2.18E + 00 | 7.25E-02 | GRM8, SLC1A1, HOMER1, GNG7, GRIK1 |
| Galpha(s) signaling | 2.11E + 00 | 5.79E-02 | RGS2, ADD3, ADCY1, GNB5, RYR1, HTR6, GNG7 |
| Cell cycle: G1/S checkpoint regulation | 2.06E + 00 | 7.58E-02 | PA2G4, HDAC8, SMAD3, SMAD4, CDKN1B |
| Beta-adrenergic signaling | 2.04E + 00 | 5.71E-02 | ADCY1, GNB5, HRAS, PRKCH, GNG7, PRKCB |
| Phospholipase C signaling | 2.04E + 00 | 4.23E-02 | ARHGEF10, MPRIP, HDAC8, RHOT2, ADCY1, GNB5, ITGA5, HRAS, PRKCH, GNG7, PRKCB |
| Neuregulin signaling | 2.00E + 00 | 5.88E-02 | ITGA5, HRAS, PRKCH, CDKN1B, PTEN, PRKCB |
| G Beta gamma signaling | 2.00E + 00 | 5.13E-02 | ADCY1, GNB5, HRAS, PRKCH, GNG7, PRKCB |
| RAR activation | 1.98E + 00 | 4.76E-02 | SMAD3, ADCY1, SMAD4, PRKCH, ERCC2, PTEN, PPARGC1A, RBP4, PRKCB |
| Virus entry via endocytic pathways | 1.97E + 00 | 6.06E-02 | ITGA5, TFRC, HRAS, PRKCH, CXADR, PRKCB |
| Chronic myeloid leukemia signaling | 1.86E + 00 | 5.71E-02 | PA2G4, HDAC8, SMAD3, SMAD4, HRAS, CDKN1B |
| Glioma signaling | 1.84E + 00 | 5.36E-02 | PA2G4, CAMK1G, HRAS, PRKCH, PTEN, PRKCB |
| Axonal guidance signaling | 1.77E + 00 | 3.42E-02 | SHH, GNB5, HRAS, SEMA6B, ITGA5, FZD1, SLIT2, GIT1, GNG7, NTNG1, SEMA3A, SUFU, BAIAP2, ABLIM2, PRKCH, PRKCB |
| Breast cancer regulation by stathmin1 | 1.73E + 00 | 4.35E-02 | ARHGEF10, ADCY1, GNB5, CAMK1G, HRAS, PRKCH, CDKN1B, GNG7, PRKCB |
| Molecular mechanisms of cancer | 1.60E + 00 | 3.44E-02 | SHH, PA2G4, SMAD3, RHOT2, HRAS, FZD1, ARHGEF10, SUFU, ADCY1, SMAD4, PRKCH, CDKN1B, PRKCB |
| Renin-angiotensin signaling | 1.60E + 00 | 4.80E-02 | ADCY1, HRAS, SHC3, PRKCH, STAT3, PRKCB |
| CREB signaling in neurons | 1.56E + 00 | 3.94E-02 | GRM8, ADCY1, GNB5, HRAS, PRKCH, GNG7, GRIK1, PRKCB |
| Androgen signaling | 1.55E + 00 | 4.17E-02 | SMAD3, GNB5, PRKCH, ERCC2, GNG7, PRKCB |
| ErbB2-ErbB3 signaling | 1.51E + 00 | 6.67E-02 | HRAS, STAT3, CDKN1B, PTEN |
| Calcium signaling | 1.48E + 00 | 3.79E-02 | TNNT1, HDAC8, CAMK1G, TPM2, RYR1, TRPC4, CASQ2, GRIK1 |
| 14-3-3-mediated signaling | 1.45E + 00 | 4.96E-02 | STK11, TSC2, HRAS, PRKCH, CDKN1B, PRKCB |
| P2Y purigenic receptor signaling pathway | 1.42E + 00 | 4.35E-02 | ADCY1, GNB5, HRAS, PRKCH, GNG7, PRKCB |
| PTEN signaling | 1.42E + 00 | 4.44E-02 | INPP5F, FLT1, ITGA5, HRAS, CDKN1B, PTEN |
| IL-8 signaling | 1.41E + 00 | 3.90E-02 | FLT1, RHOT2, GNB5, HRAS, PRKCH, IRAK3, GNG7, PRKCB |
| cAMP-mediated signaling | 1.41E + 00 | 4.02E-02 | RGS2, GRM8, NPY1R, DUSP6, ADCY1, CAMK1G, ADRA2C, HTR6, STAT3 |
Microarray data were analyzed through the use of IPA (Ingenuity® Systems, http://www.ingenuity.com).
The p-value was calculated using the right-tailed Fisher Exact Test, considering the number of molecules participating in a given pathway and the total number of molecules associated with that pathway in Ingenuity’s knowledge base.